Lupin jumps marginally after generic drug launch

Shares of pharma major Lupin saw a marginal jump today after it announced launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infection in children.
On BSE, the scrip opened at Rs 1,482.85 and touched an early high of Rs 1,487.05, up 0.84 per cent. At 1056 hours, it was trading at Rs 1,479.75, up by 0.34 per cent.
Similarly, on NSE, the stock opened at Rs 1,485 before climbing 0.91 per cent to a high of Rs 1,487.65. At 1056 hours, it was trading 0.25 per cent up at Rs 1,477.95.
Having received an approval from the US Food and Drug Administration (USFDA) earlier to market a generic equivalent of PF Prism CV's Vfend tablets, 50 mg and 200 mg and Vfend Oral Suspension 40 mg/mL, Lupin said yesterday that it had launched the same in the US market.

The medicines are indicated for use in patients 12 years of age and older in the treatment of fungal infections, including invasive Aspergillosis, Candidemia in non-neutropenic patients.